Overview
This workshop brings together experts, early-career researchers, and patient representatives to advance thoracic oncology research. It focuses on low-dose CT lung cancer screening (LDCT LCS), pulmonary nodule management, and early-stage management of non-small cell lung cancer (NSCLC), aiming to develop guidelines, address research gaps, and integrate real-world data and patient perspectives.
The EU-funded projects IDERHA, OPTIMA, and SOLACE are key to this workshop, providing essential expertise, resources, and state-of-the-art data platforms. They promote researcher collaboration, support evidence-based guidelines, and drive innovation in thoracic oncology by integrating AI, biomarkers, and digital infrastructure to enhance clinical and translational research.
Target audience
- Clinical researchers
- Pathologists
- Patients
- Policy makers
- Radiologists
- Thoracic oncologists
- Epidemiologists
Organising committee
Torsten Blum
Workshop Chair
Marjolein Heuvelmans
Workshop Chair
Faculty: J. Chorostowska-Wynimko, H. Kauczor, R. Ledda, M. Pereira Catarata, A. Kremer, I. Tietzova, A. Frille, L. Seijo, W. van Geffen, M. Rodriguez Perez, E. Senerth, T. Tonia, U. Pastorino, R. Morgan, H. Prosch, L. M. Montuenga, A. Kremer, G. Hardavella, S. Evans Axelsson, M. Zigman, S. Madan, M. Chevli, I. Belina, D. Newby
This scientific workshop is made possible with the support of the following projects:
- OPTIMA is funded through the IMI2 Joint Undertaking and is listed under grant agreement No. 101034347. IMI2 receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.
- SOLACE is co-funded under the EU4Health Programme 2021-2027 under grant agreement no. 101101187. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.
- IDERHA is supported by the Innovative Health Initiative Joint Undertaking (JU) under grant agreement No 101112135. The JU receives support from the European Union's Horizon Europe research and innovation programme and life science industries represented by COCIR, EFPIA / Vaccines Europe, EuropaBio and MedTech Europe. In addition, there are financial and/or in kind contributions from our Swiss and UK partners. The UK participant is supported by UKRI grant No 10079453 (National Institute for Health and Care Excellence).